Tempest Therapeutics shares are trading higher after the company announced the TPST-1120 arm improved all efficacy endpoints vs SoC control in a study.
Portfolio Pulse from Benzinga Newsdesk
Tempest Therapeutics shares are trading higher after the company announced that the TPST-1120 arm improved all efficacy endpoints compared to the standard of care (SoC) control in a study.
June 20, 2024 | 11:54 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tempest Therapeutics shares are experiencing a rise following the announcement that the TPST-1120 arm outperformed the standard of care in all efficacy endpoints in a study.
The positive study results for TPST-1120 are likely to boost investor confidence and drive the stock price higher in the short term. The improvement in all efficacy endpoints compared to the standard of care is a significant achievement for Tempest Therapeutics.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100